Vanessa A. Fabrizio - Concepedia

Author

Vanessa A. Fabrizio

Memorial Sloan Kettering Cancer Center ORCID

Also Known As

V.A. Fabrizio, Vanessa A Fabrizio, Vanessa A. Fabrizio, Vanessa Fabrizio

Publications

587

Citations

H-Index

Concepts

All Affiliations

Memorial Sloan Kettering Cancer Center Cornell University Emory University Medical College of Wisconsin Cincinnati Children's Hospital Medical Center

About

Vanessa A. Fabrizio is an author at Memorial Sloan Kettering Cancer Center specializing in medicine, cell transplantation, and hematology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	259
2	Immunology	4	4	259
3	Health Sciences	3	3	156
4	Cellular Therapies	3	3	185
5	Marrow Transplantation	1	1	21

Vanessa A. Fabrizio

Publications

502

Citations

H-Index

Page 1

	Year	Citations
Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy Vanessa A. Fabrizio, Jaap Jan Boelens, Audrey Mauguen, Blood Advances Cell TherapyOptimal Fludarabine ExposureImmunologyImmunotherapyHematological Malignancy	2021	103
Tisagenlecleucel outcomes in relapsed/refractory extramedullary ALL: a Pediatric Real World CAR Consortium Report Vanessa A. Fabrizio, Christine L. Phillips, Adam Lane, Blood Advances Isolated Cns RelapseImmunologySurgeryTisagenlecleucel OutcomesImmunotherapy	2021	74
Outcomes After Nonresponse and Relapse Post-Tisagenlecleucel in Children, Adolescents, and Young Adults With B-Cell Acute Lymphoblastic Leukemia Liora M. Schultz, Anne Eaton, Christina Baggott, Journal of Clinical Oncology	2022	71
Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemia Amy Moskop, Lauren Pommert, Christina Baggott, Blood Advances Cell TherapyImmunodeficienciesImmunologyPharmacotherapyImmunotherapy	2022	61
Higher doses of tisagenlecleucel are associated with improved outcomes: a report from the pediatric real-world CAR consortium Heather E. Stefanski, Anne Eaton, Christina Baggott, Blood Advances	2022	50
Disease Burden Impacts Outcomes in Pediatric and Young Adult B-Cell Acute Lymphoblastic Leukemia after Commercial Tisagenlecleucel: Results from the Pediatric Real World CAR Consortium (PRWCC) Liora M. Schultz, Christina Baggott, Snehit Prabhu, Blood	2020	38
Adoptive therapy with CMV-specific cytotoxic T lymphocytes depends on baseline CD4+ immunity to mediate durable responses Vanessa A. Fabrizio, Irene Rodriguez-Sanchez, Audrey Mauguen, Blood Advances	2021	35
Low toxicity and favorable overall survival in relapsed/refractory B-ALL following CAR T cells and CD34-selected T-cell depleted allogeneic hematopoietic cell transplant Vanessa A. Fabrizio, Nancy A. Kernan, Farid Boulad, Bone Marrow Transplantation Car T CellsCell TherapyTransplantationLow ToxicityMedicine	2020	21
HLH-like toxicities predict poor survival after the use of tisagenlecleucel in children and young adults with B-ALL Kevin O. McNerney, Stephanie J. Si Lim, Kyle Ishikawa, Blood Advances	2023	21
Project EVOLVE: an international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia Sara Silbert, Alexander W. Rankin, Chloe Hoang, Blood	2025	16

Page 1